Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hut 8 Corp (HUT) vs Eli Lilly And Co (LLY) Price & Performance

Hut 8 CorpTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Eli Lilly And Co — how do they compare? Hut 8 Corp trades at $90.75 (market cap $10.94B), while Eli Lilly And Co trades at $1,220.99 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 98.7× Hut 8 Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.

HUTLLY
Market Cap
$10.94B$1.08T
Sector
TechnologyHealth
52-Week High
$133.02$1.24K
52-Week Low
$21.37$639.43
Enterprise Value
$18.38B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hut 8 Corp

HUT trades at $90.77, up 5.97% on the day, amid a broader neocloud stock rally. The technical picture is bearish with resistance at $92 and support at $87. Fundamentally, the company reported a net loss of $226.15 million in 2025 despite revenue growth, with a negative net income margin of -188.59%. Recent news highlights a significant $26.6 billion contracted backlog and $7.5 billion in project financing for AI data center development, driving investor optimism about its strategic pivot.

The outlook is mixed: strong analyst buy ratings (93.75%) and a $165.11 price target suggest upside, but persistent losses, high valuation ratios, and execution risks on new projects pose challenges. The stock's near-term direction will hinge on translating its AI infrastructure backlog into profitable growth and achieving positive cash flow.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

Read more on HUT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY